Yahoo Home 10 Best Immunotherapy Stocks To Buy Now
In this article, we discuss 10 best immunotherapy stocks to buy now. If you want to read about some more immunotherapy stocks, go directly to 5 Best Immunotherapy Stocks To Buy Now.
The global immunotherapy market is rapidly evolving as technological, regulatory, and economic trends combine to alter the growth and risk dynamics within the industry. According to a report by market research firm BCC Research, the global market for immunotherapy drugs could be worth more than $204 billion in value by 2025, up from $139 billion in 2020, representing an annual growth rate of close to 8%. The estimates are based on analysis of new products, regulatory scenarios, and the challenges and opportunities affecting market growth.
Within the immunotherapy universe, cancer immunotherapies are the largest market. According to data compiled by the American Cancer Society, of all drug approvals between 2010 and 2018, 27% were cancer therapies, compared with 4% in the 1980s. Despite this explosive growth, cancer remains the leading cause of death globally, accounting for nearly 10 million deaths in 2020. To put this figure into context, the coronavirus pandemic killed about 3 million people in the same year.
Growth Drivers and Challenges Abound for Immunotherapy Marketplace
Investors eager to take advantage of the growth opportunities in the sector should monitor some of the best immunotherapy stocks that include Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV). In recent years, immunotherapy research has evolved to include trials studying combinations such as kill switches, removable protein masks, or linkers that bring immune cells and tumor cells into proximity in order to tamp down side-effects.
There are several reasons that are holding back even faster development within the immunotherapy marketplace. These include the high cost of cancer immunotherapies, strict rules and regulations related to government policies in some regions, manufacturing process related complexities, and concern regarding side effects. The growth drivers, on the other hand, include the increasing prevalence of autoimmune diseases among adults and growing investments in the research and funding of cancer.
Our Methodology
The companies that operate in the immunotherapy sector were selected for the list. In order to provide readers with some additional context for their investment choices, the business fundamentals and analyst ratings for these stocks are also discussed. The latest pipeline drugs of these firms, under various stages of their development, are mentioned as well for further clarity. A database of around 900 elite hedge funds tracked by Insider Monkey in the second quarter of 2022 was used to identify the number of hedge funds that hold stakes in each firm.
Copyright: kadmy / 123RF Stock Photo
Best Immunotherapy Stocks To Buy Now
10. Evaxion Biotech A/S (NASDAQ:EVAX)
Number of Hedge Fund Holders: 2
Evaxion Biotech A/S (NASDAQ:EVAX) is a clinical-stage biotech company that engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. It is one of the best immunotherapy stocks to invest in. Evaxion Biotech A/S (NASDAQ:EVAX) recently revealed that it enrolled the first patient in a global phase 2b trial of its immunotherapy EVX-01 to treat melanoma, a type of skin cancer. The trial is being conducted at sites in the US, Europe, and Australia in collaboration with drug giant Merck, which is supplying the trial with its blockbuster drug Keytruda.
On July 18, investment advisory Oppenheimer assumed coverage of Evaxion Biotech A/S (NASDAQ:EVAX) stock with an Outperform rating and a $16 price target. Analyst Jeff Jones issued the ratings update.
At the end of the second quarter of 2022, 2 hedge funds in the database of Insider Monkey held stakes worth $185,000 in Evaxion Biotech A/S (NASDAQ:EVAX), compared to 2 in the previous quarter worth $1.3 million.
Among the hedge funds being tracked by Insider Monkey, Chicago-based investment firm Citadel Investment Group is a leading shareholder in Evaxion Biotech A/S (NASDAQ:EVAX), with 333,100 shares worth more than $650,000.
Just like Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), Evaxion Biotech A/S (NASDAQ:EVAX) is one of the best immunotherapy stocks to buy right now.
9. ThermoGenesis Holdings, Inc. (NASDAQ:THMO)
Number of Hedge Fund Holders: 3
ThermoGenesis Holdings, Inc. (NASDAQ:THMO) develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It is one of the top immunotherapy stocks to invest in. The company currently markets a full suite of solutions for automated clinical bio-banking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.
On August 11, the company reported earnings for the second quarter of 2022, posting a revenue of $3 million, up more than 37% compared to the revenue over the same period last year. The firm is based in California and was founded in 1986.
At the end of the second quarter of 2022, 3 hedge funds in the database of Insider Monkey held stakes worth $68,000 in ThermoGenesis Holdings, Inc. (NASDAQ:THMO). Among the hedge funds being tracked by Insider Monkey, Chicago-based investment firm Citadel Investment Group is a leading shareholder in ThermoGenesis Holdings, Inc. (NASDAQ:THMO), with 195,192 shares worth more than $54,000.
8. Greenwich LifeSciences, Inc. (NASDAQ:GLSI)
Number of Hedge Fund Holders: 6
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is a clinical stage biopharmaceutical company that focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. It is one of the premier immunotherapy stocks to invest in. Greenwich LifeSciences, Inc. (NASDAQ:GLSI) recently entered into an Open Market Sale Agreement with Jefferies, wherein it may issue and sell from time to time shares at a par value of $0.001 per unit. Greenwich LifeSciences, Inc. (NASDAQ:GLSI) also recently reported that the US Food and Drug Administration had removed a clinical hold on a phase 3 trial of a breast cancer treatment, allowing the trial to progress.
On July 12, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Greenwich LifeSciences, Inc. (NASDAQ:GLSI) stock with a $78 price target, predicting that the FLAMINGO-01 breast cancer trial of the firm would proceed as planned.
Among the hedge funds being tracked by Insider Monkey, NewYork-based investment firm Renaissance Technologies is a leading shareholder in Greenwich LifeSciences, Inc. (NASDAQ:GLSI), with 105,159 shares worth more than $891,000. At the end of the second quarter of 2022, 6 hedge funds in the database of Insider Monkey held stakes worth $2.8 million in Greenwich LifeSciences, Inc. (NASDAQ:GLSI), compared to 1 the preceding quarter worth $410,000.
7. ImmunityBio, Inc. (NASDAQ:IBRX)
Number of Hedge Fund Holders: 8
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company that engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. It is one of the major immunotherapy stocks to invest in. ImmunityBio, Inc. (NASDAQ:BRX) recently revealed that the drug authorities in the US had accepted for review the company's biologics license application (BLA) for its agonist N-803, a treatment of bladder cancer carcinoma in situ. The exact indication for N-803 is for the treatment of patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.
On August 03, Jefferies analyst Kelly Shi initiated coverage of ImmunityBio, Inc. (NASDAQ:BRX) stock with a Buy rating and lowered price target to $8 from $10, stressing that the price target is lowered to reflect the recent pullback and current market conditions.
At the end of the second quarter of 2022, 8 hedge funds in the database of Insider Monkey held stakes worth $11 million in ImmunityBio, Inc. (NASDAQ:IBRX), compared to 7 the preceding quarter worth $7 million.
6. UroGen Pharma Ltd. (NASDAQ:URGN)
Number of Hedge Fund Holders: 11
UroGen Pharma Ltd. (NASDAQ:URGN) is a biotechnology company that engages in the development and commercialization of novel solutions for specialty cancers and urothelial diseases. It is one of the elite immunotherapy stocks to invest in. UroGen Pharma Ltd. (NASDAQ:URGN) stock has risen in the past week after the company said that the US FDA had authorized an extension of the in-use period for Jelmyto (mitomycin) for pyelocalyceal solution admixture from 8 hours to 96 hours after reconstitution of the product.
On April 27, Berenberg analyst Anita Dushyanth initiated coverage of UroGen Pharma Ltd. (NASDAQ:URGN) stock with a Buy rating and a $20 price target, denoting that there was a considerable opportunity for UroGen's novel RTGel drug-delivery technology in both high- and low-grade bladder cancers given that bladder cancer has a high rate of recurrence and is currently being treated predominantly with surgery.
Among the hedge funds being tracked by Insider Monkey, Oregon-based investment firm Stonepine Capital is a leading shareholder in UroGen Pharma Ltd. (NASDAQ:URGN), with 1.1 million shares worth more than $9 million. At the end of the second quarter of 2022, 11 hedge funds in the database of Insider Monkey held stakes worth $33 million in UroGen Pharma Ltd. (NASDAQ:URGN), compared to 9 the preceding quarter worth $19 million.
In addition to Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best immunotherapy stocks to buy right now according to smart investors.
Click to continue reading and see 5 Best Immunotherapy Stocks To Buy Now.
Suggested Articles:
Disclosure. None. 10 Best Immunotherapy Stocks To Buy Now is originally published on Insider Monkey.
